{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T18:17:44Z","timestamp":1722709064170},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00125-019-4958-2","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T10:55:07Z","timestamp":1563965707000},"page":"1529-1538","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical aspects of heart failure in individuals with diabetes"],"prefix":"10.1007","volume":"62","author":[{"given":"Christa D.","family":"Bowes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian F.","family":"Lien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"issue":"1","key":"4958_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","volume":"61","author":"G Jia","year":"2018","unstructured":"Jia G, Whaley-Connell A, Sowers JR (2018) Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 61(1):21\u201328. \n                    https:\/\/doi.org\/10.1007\/s00125-017-4390-4","journal-title":"Diabetologia"},{"issue":"22","key":"4958_CR2","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","volume":"103","author":"C Iribarren","year":"2001","unstructured":"Iribarren C, Karter AJ, Go AS et al (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation 103(22):2668\u20132673. \n                    https:\/\/doi.org\/10.1161\/01.CIR.103.22.2668","journal-title":"Circulation"},{"issue":"7258","key":"4958_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258):405\u2013412. \n                    https:\/\/doi.org\/10.1136\/bmj.321.7258.405","journal-title":"BMJ"},{"issue":"1","key":"4958_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34(1):29\u201334. \n                    https:\/\/doi.org\/10.1016\/0002-9149(74)90089-7","journal-title":"Am J Cardiol"},{"issue":"8","key":"4958_CR5","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","volume":"27","author":"GA Nichols","year":"2004","unstructured":"Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27(8):1879\u20131884. \n                    https:\/\/doi.org\/10.2337\/diacare.27.8.1879","journal-title":"Diabetes Care"},{"issue":"7","key":"4958_CR6","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","volume":"93","author":"JK Boyer","year":"2004","unstructured":"Boyer JK, Thanigaraj S, Schechtman KB, Perez JE (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93(7):870\u2013875. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2003.12.026","journal-title":"Am J Cardiol"},{"issue":"11","key":"4958_CR7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F et al (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 29(11):1377\u20131385. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehn153","journal-title":"Eur Heart J"},{"issue":"16","key":"4958_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1053\/euhj.1999.2043","volume":"21","author":"N Suskin","year":"2000","unstructured":"Suskin N, McKelvie RS, Burns RJ et al (2000) Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 21(16):1368\u20131375. \n                    https:\/\/doi.org\/10.1053\/euhj.1999.2043","journal-title":"Eur Heart J"},{"issue":"9677","key":"4958_CR9","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373(9677):1765\u20131772. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)60697-8","journal-title":"Lancet"},{"key":"4958_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ahj.2005.10.008","volume":"151","author":"S Eshaghian","year":"2006","unstructured":"Eshaghian S, Horwich TB, Fonarow GC (2006) An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 151:91","journal-title":"Am Heart J"},{"issue":"5","key":"4958_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2009.04.049","volume":"54","author":"D Aguilar","year":"2009","unstructured":"Aguilar D, Bozkurt B, Ramasubbu K, Deswal A (2009) Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 54(5):422\u2013428. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2009.04.049","journal-title":"J Am Coll Cardiol"},{"key":"4958_CR12","unstructured":"US Food & Drug Administration (2018) Guidance for industry: diabetes mellitus \u2014 evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from \n                    www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071627.pdf\n                    \n                  . Accessed 5 Jan 2019"},{"issue":"1","key":"4958_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4158\/CS-2017-0153","volume":"24","author":"AJ Garber","year":"2018","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI et al (2018) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract 24(1):91\u2013120. \n                    https:\/\/doi.org\/10.4158\/CS-2017-0153","journal-title":"Endocr Pract"},{"issue":"4","key":"4958_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4):319\u2013328. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1203858","journal-title":"N Engl J Med"},{"issue":"6","key":"4958_CR15","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2337\/dc09-2227","volume":"33","author":"MR MacDonald","year":"2010","unstructured":"MacDonald MR, Eurich DT, Majumdar SR et al (2010) Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 33(6):1213\u20131218. \n                    https:\/\/doi.org\/10.2337\/dc09-2227","journal-title":"Diabetes Care"},{"issue":"dec03 1","key":"4958_CR16","doi-asserted-by":"publisher","first-page":"b4731","DOI":"10.1136\/bmj.b4731","volume":"339","author":"I Tzoulaki","year":"2009","unstructured":"Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of CVD and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339(dec03 1):b4731. \n                    https:\/\/doi.org\/10.1136\/bmj.b4731","journal-title":"BMJ"},{"key":"4958_CR17","doi-asserted-by":"publisher","first-page":"e005379","DOI":"10.1161\/JAHA.116.005379","volume":"6","author":"CL Roumie","year":"2017","unstructured":"Roumie CL, Min JY, D\u02bcAgostino McGowan L et al (2017) Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J Am Heart Assoc 6:e005379","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"4958_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"4958_CR19","unstructured":"Novo Nordisk (2017) Victoza\u00ae approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events. Available from \n                    www.novonordisk.com\/content\/Denmark\/HQ\/www-novonordisk-com\/en_gb\/home\/media\/news-details.1255872.html\n                    \n                  . Accessed 5 Jan 2019"},{"issue":"19","key":"4958_CR20","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"4958_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2017.02.005","volume":"187","author":"RJ Mentz","year":"2017","unstructured":"Mentz RJ, Bethel MA, Gustavson S et al (2017) Baseline characteristics of patients enrolled in the Exenatide study of cardiovascular event lowering (EXSCEL). Am Heart J 187:1\u20139. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2017.02.005","journal-title":"Am Heart J"},{"issue":"23","key":"4958_CR22","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247\u20132257. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"issue":"13","key":"4958_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228\u20131239. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1612917","journal-title":"N Engl J Med"},{"issue":"10157","key":"4958_CR24","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and CVD (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519\u20131529. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet"},{"key":"4958_CR25","doi-asserted-by":"publisher","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","DOI":"10.1016\/S0140-6736(19)31149-3"},{"issue":"22","key":"4958_CR26","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"4958_CR27","unstructured":"US Food & Drug Administration (2016) FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. Available from \n                    www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm531517.htm\n                    \n                  . Accessed 5 Jan 2019"},{"issue":"19","key":"4958_CR28","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37(19):1526\u20131534. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv728","journal-title":"Eur Heart J"},{"issue":"4","key":"4958_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW, Neal B, Perkovic V et al (2018) Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137(4):323\u2013334. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032038","journal-title":"Circulation"},{"issue":"7","key":"4958_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"4958_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ et al (2017) Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 136:249\u2013259","journal-title":"Circulation"},{"issue":"4","key":"4958_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2018) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"9","key":"4958_CR33","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1681\/ASN.2013060588","volume":"25","author":"TD Pessoa","year":"2014","unstructured":"Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G (2014) Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25(9):2028\u20132039. \n                    https:\/\/doi.org\/10.1681\/ASN.2013060588","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4958_CR34","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","volume":"2","author":"M Packer","year":"2017","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Zannad F (2017) Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2(9):1025\u20131029. \n                    https:\/\/doi.org\/10.1001\/jamacardio.2017.2275","journal-title":"JAMA Cardiol"},{"issue":"9493","key":"4958_CR35","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279\u20131289. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9","journal-title":"Lancet"},{"issue":"9681","key":"4958_CR36","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681):2125\u20132135. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)60953-3","journal-title":"Lancet"},{"issue":"18","key":"4958_CR37","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I et al (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130(18):1579\u20131588. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.010389","journal-title":"Circulation"},{"issue":"14","key":"4958_CR38","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317\u20131326. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"issue":"9982","key":"4958_CR39","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385(9982):2067\u20132076. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)62225-X","journal-title":"Lancet"},{"issue":"7","key":"4958_CR40","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2337\/dc16-0303","volume":"39","author":"WB White","year":"2016","unstructured":"White WB, Kupfer S, Zannad F et al (2016) Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial. Diabetes Care 39(7):1267\u20131273. \n                    https:\/\/doi.org\/10.2337\/dc16-0303","journal-title":"Diabetes Care"},{"issue":"3","key":"4958_CR41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373(3):232\u2013242. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1501352","journal-title":"N Engl J Med"},{"issue":"2","key":"4958_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2337\/dc14-1459","volume":"38","author":"OH Yu","year":"2015","unstructured":"Yu OH, Filion KB, Azoulay L, Patenaude V, Majdan A, Suissa S (2015) Incretin-based drugs and the risk of congestive heart failure. Diabetes Care 38(2):277\u2013284. \n                    https:\/\/doi.org\/10.2337\/dc14-1459","journal-title":"Diabetes Care"},{"issue":"6","key":"4958_CR43","doi-asserted-by":"publisher","first-page":"e007959","DOI":"10.1136\/bmjopen-2015-007959","volume":"5","author":"CB Giorda","year":"2015","unstructured":"Giorda CB, Picariello R, Tartaglino B et al (2015) Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study. BMJ Open 5(6):e007959. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2015-007959","journal-title":"BMJ Open"},{"issue":"1","key":"4958_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321(1):69\u201379. \n                    https:\/\/doi.org\/10.1001\/jama.2018.18269","journal-title":"JAMA"},{"issue":"5","key":"4958_CR45","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/01.CIR.0000154542.13412.B1","volume":"111","author":"FA Masoudi","year":"2005","unstructured":"Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111(5):583\u2013590. \n                    https:\/\/doi.org\/10.1161\/01.CIR.0000154542.13412.B1","journal-title":"Circulation"},{"issue":"3","key":"4958_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7326\/M16-1901","volume":"166","author":"MJ Crowley","year":"2017","unstructured":"Crowley MJ, Diamantidis CJ, McDuffie JR et al (2017) Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166(3):191\u2013200. \n                    https:\/\/doi.org\/10.7326\/M16-1901","journal-title":"Ann Intern Med"},{"issue":"3","key":"4958_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cardfail.2009.12.007","volume":"16","author":"G Giamouzis","year":"2010","unstructured":"Giamouzis G, Triposkiadis F, Butler J (2010) Metformin use in patients with diabetes mellitus and heart failure: friend or foe? J Card Fail 16(3):207\u2013210. \n                    https:\/\/doi.org\/10.1016\/j.cardfail.2009.12.007","journal-title":"J Card Fail"},{"issue":"Suppl 1","key":"4958_CR48","doi-asserted-by":"publisher","first-page":"s196","DOI":"10.1016\/j.jcjd.2017.10.026","volume":"42","author":"KA Connelly","year":"2018","unstructured":"Connelly KA, Gilbert RE, Liu P (2018) Treatment of diabetes in people with heart failure. Can J Diabetes 42(Suppl 1):s196\u2013s200. \n                    https:\/\/doi.org\/10.1016\/j.jcjd.2017.10.026","journal-title":"Can J Diabetes"},{"issue":"5","key":"4958_CR49","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovic","year":"2018","unstructured":"Seferovic PM, Petrie MC, Filippatos GS et al (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20(5):853\u2013872. \n                    https:\/\/doi.org\/10.1002\/ejhf.1170","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"4958_CR50","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J et al (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61(12):2461\u20132498. \n                    https:\/\/doi.org\/10.1007\/s00125-018-4729-5","journal-title":"Diabetologia"},{"issue":"5","key":"4958_CR51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM et al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500\u2013508. \n                    https:\/\/doi.org\/10.1001\/jama.2016.10260","journal-title":"JAMA"},{"issue":"1","key":"4958_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69\u201377. \n                    https:\/\/doi.org\/10.1002\/ejhf.657","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"4958_CR53","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327\u20131335. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1305889","journal-title":"N Engl J Med"},{"issue":"5","key":"4958_CR54","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.numecd.2016.02.006","volume":"26","author":"E Raschi","year":"2016","unstructured":"Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F (2016) Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA adverse event reporting system. Nutr Metab Cardiovasc Dis 26(5):380\u2013386. \n                    https:\/\/doi.org\/10.1016\/j.numecd.2016.02.006","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"4958_CR55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","volume":"6","author":"JJV McMurray","year":"2018","unstructured":"McMurray JJV, Ponikowski P, Bolli GB et al (2018) Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 6(1):8\u201317. \n                    https:\/\/doi.org\/10.1016\/j.jchf.2017.08.004","journal-title":"JACC Heart Fail"},{"issue":"1","key":"4958_CR56","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ahj.2004.07.005","volume":"149","author":"S Smooke","year":"2005","unstructured":"Smooke S, Horwich TB, Fonarow GC (2005) Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149(1):168\u2013174. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2004.07.005","journal-title":"Am Heart J"},{"issue":"9","key":"4958_CR57","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","volume":"41","author":"PG Shekelle","year":"2003","unstructured":"Shekelle PG, Rich MW, Morton SC et al (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41(9):1529\u20131538. \n                    https:\/\/doi.org\/10.1016\/S0735-1097(03)00262-6","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"4958_CR58","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.amjcard.2005.07.061","volume":"96","author":"AA Carr","year":"2005","unstructured":"Carr AA, Kowey PR, Devereux RB et al (2005) Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 96(11):1530\u20131536. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2005.07.061","journal-title":"Am J Cardiol"},{"issue":"1","key":"4958_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cpcardiol.2014.09.002","volume":"40","author":"A Dei Cas","year":"2015","unstructured":"Dei Cas A, Fonarow GC, Gheorghiade M, Butler J (2015) Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol 40(1):7\u201343. \n                    https:\/\/doi.org\/10.1016\/j.cpcardiol.2014.09.002","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"4958_CR60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1559-4572.2008.00017.x","volume":"3","author":"RA Phillips","year":"2008","unstructured":"Phillips RA, Fonseca V, Katholi RE et al (2008) Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the glycemic effects in diabetes mellitus: carvedilol-metoprolol comparison in hypertensives (GEMINI) study. J Cardiometab Syndr 3(4):211\u2013217. \n                    https:\/\/doi.org\/10.1111\/j.1559-4572.2008.00017.x","journal-title":"J Cardiometab Syndr"},{"issue":"10","key":"4958_CR61","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N Engl J Med 341(10):709\u2013717. \n                    https:\/\/doi.org\/10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"issue":"1","key":"4958_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"4958_CR63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ahj.2018.07.002","volume":"204","author":"S Korol","year":"2018","unstructured":"Korol S, White M, O\u02bcMeara E et al (2018) A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: a randomized controlled double-blind trial. Am Heart J 204:190\u2013195. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2018.07.002","journal-title":"Am Heart J"},{"issue":"11","key":"4958_CR64","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"issue":"5","key":"4958_CR65","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","volume":"5","author":"JP Seferovic","year":"2017","unstructured":"Seferovic JP, Claggett B, Seidelmann SB et al (2017) Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5(5):333\u2013340. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(17)30087-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"4958_CR66","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D et al (2013) Rationale, design, and baseline characteristics of the Canagliflozin cardiovascular assessment study (CANVAS)\u2014a randomized placebo-controlled trial. Am Heart J 166(2):217\u2013223.e11. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2013.05.007","journal-title":"Am Heart J"},{"issue":"3","key":"4958_CR67","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/dom.12829","volume":"19","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR et al (2017) Rationale, design and baseline characteristics of the Canagliflozin cardiovascular assessment study-renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 19(3):387\u2013393. \n                    https:\/\/doi.org\/10.1111\/dom.12829","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-019-4958-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T23:03:50Z","timestamp":1595545430000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-019-4958-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4958"],"URL":"https:\/\/doi.org\/10.1007\/s00125-019-4958-2","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"13 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LFL has served as a consultant for Tandem, Novo Nordisk, Merck, Eli Lilly and Sanofi and receives royalties from Springer Inc. JB has received research support from the National Institutes of Health, Patient Centered Outcomes Research Institute and the European Union and serves as a consultant for Adrenomed, Amgen, Array, AstraZeneca, Bayer, Berlin Cures, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmaceutical, Janssen, Lantheus, Luitpold, Medtronic, Merck, Novartis, Relypsa, Roche, Sanofi, StealthPeptide, SC Pharma, Vifor and ZS Pharma. CDB reports no duality of interest associated with this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}